Atlas Venture Fund Xii, L.P. is > 10% Shareholder of Aerovate Therapeutics, Inc.. Currently has a direct ownership of 2.33 Million shares of AVTE, which is worth approximately $5.7 Million. The most recent transaction as insider was on Jul 15, 2022, when has been sold 310,388 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.33M
0% 3M change
0% 12M change
Total Value Held $5.7 Million

Atlas Venture Fund XII, L.P. Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jul 15 2022
SELL
Other acquisition or disposition
-
310,388 Reduced 11.76%
2,327,909 Common Stock
Apr 01 2022
SELL
Other acquisition or disposition
-
465,582 Reduced 15.0%
2,638,297 Common Stock
Jul 02 2021
BUY
Open market or private purchase
$7,499,996 $14.0 p/Share
535,714 Added 14.72%
3,103,879 Common Stock
Jul 02 2021
BUY
Conversion of derivative security
-
2,568,165 Added 50.0%
2,568,165 Common Stock

Also insider at

VIGL
Vigil Neuroscience, Inc. Healthcare
AVF

Atlas Venture Fund Xii, L.P.

> 10% Shareholder
Cambridge, MA

Track Institutional and Insider Activities on AVTE

Follow Aerovate Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AVTE shares.

Notify only if

Insider Trading

Get notified when an Aerovate Therapeutics, Inc. insider buys or sells AVTE shares.

Notify only if

News

Receive news related to Aerovate Therapeutics, Inc.

Track Activities on AVTE